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CObjectives: To present a case study involving the reduction in inci-
dence of febrile neutropenia (FN) after chemotherapy with granulocyte
colony–stimulating factors (G-CSFs), illustrating difficulties that may
arise when following the common preference for direct evidence over
indirect evidence.Methods: Evidence of the efficacy of treatments was
identified from two previous systematic reviews. We used Bayesian
evidence synthesis to estimate relative treatment effects based on di-
rect evidence, indirect evidence, and both pooled together. We checked
for inconsistency between direct and indirect evidence and explored
the role of one specific trial using cross-validation. A subsequent re-
view identified further studies not available at the time of the original
analysis. We repeated the analyses on the enlarged evidence base.
Results: We found substantial inconsistency in the original evidence
base. The median odds ratio of FN for primary pegfilgrastim versus no
primary G-CSF was 0.06 (95% credible interval: 0.02–0.19) based on di-
rect evidence, but 0.27 (95% credible interval: 0.13–0.53) based on indi- O
mary
al So
oi:10.1016/j.jval.2011.05.042ect evidence (P value for consistency hypothesis 0.027). The additional
rials were consistent with the earlier indirect, rather than the direct,
vidence, and there was no inconsistency between direct and indirect
stimates in the updated evidence. The earlier inconsistency was due
o one trial comparing primary pegfilgrastim with no primary G-CSF.
redictive cross-validation showed that this study was inconsistent
ith the evidence as a whole and with other trials making this
omparison. Conclusions: Both the Cochrane Handbook and the NICE
ethods Guide express a preference for direct evidence. A more robust
trategy, which is in line with the accepted principles of evidence syn-
hesis, would be to combine all relevant and appropriate information,
hether direct or indirect.
eywords: Bayesian methods, febrile neutropenia, granulocyte colony–
timulating factors, methodology, mixed treatment comparison
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
There is often a need to synthesize evidence from multiple studies
when evaluating medical interventions from a clinical or health
policy perspective. Meta-analysis is an established statistical
method for this synthesis when the evidence consists of several
head-to-head comparisons of two treatments. The estimation of
the relative effectiveness of two treatments for which no head-to-
head evidence is available is known as an indirect comparison (IC)
[1]. Mixed treatment comparison (MTC) meta-analysis is a gener-
alization of standard pairwise meta-analysis that derives esti-
mates of treatment effects from a synthesis of direct and indirect
evidence. Statistical methods appear to have been discovered in-
dependently by several authors [1–3], although recently Bayesian
methods based on the previous work [2] have become popular
[4,5]. The advantage of this approach is that it “borrows strength”
from indirect evidence where direct evidence is lacking or sparse.
Skepticism has been expressed, however, regarding the validity of
MTC and the appropriateness of including indirect evidence
where direct evidence is available. This is reflected in the current
Guide to the Methods of Technology Appraisal issued by the Na-
tional Institute for Health and Clinical Excellence (NICE), which
* Address correspondence to: Jason Madan, Academic Unit of Pri
ristol, Avon, BS6 6JL UK.
E-mail: jason.madan@bris.ac.uk.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.states that “the Institute has a preference for data from head-to-
head RCTs” [6]. Also, section 16.6 of the Cochrane Collaboration
states that direct comparisons should take precedence over indi-
rect and advises that MTC should be seen as a supplement to,
rather than a replacement of, analysis of the direct evidence [7].
What is known about the reliability of indirect evidence and
the wisdom of combining it with direct evidence? First, at an em-
pirical level, studies comparing direct and indirect evidence have
found no systematic differences [8]. Where differences have been
found, they appear to have been in situations in which the doses or
treatment combinations in the direct and indirect evidence were
not comparable [8–11]. Second, at a practical level, when decisions
must be made between more than two treatments, this must be
based on a coherent and internally consistent set of estimates in
which the estimated difference between treatments A and C is the
sum of the estimated treatment differences between A and B and
B and C. Estimates with the required coherence properties are
precisely what an MTC analysis delivers. Third, at a theoretical
level, the assumptions required by an MTC analysis of AB, AC, and
BC studies are exactly the same as the assumptions that would be
required by pairwise meta-analyses of the AB and AC effects in all
these trials (assuming that all trials had all three treatments).
Health Care, University of Bristol, Cotham House, Cotham Hill,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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954 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 5 3 – 9 6 0More formally, the consistency assumptions made by MTC follow
automatically from the standard exchangeability assumptions ap-
plied over the full set of trials [12].
Every health technology assessment must begin with a defini-
ion of the target population and the candidate treatments. Before
ny statistical evidence syntheses, a careful review of clinical
eterogeneity among the included trials is necessary and, in
articular, whether this could be associated with effect modifi-
ation. The presence of recognized effect modifiers in the evi-
ence base suggests that different decisions should be made for
he different patient groups. The presence of unrecognized ef-
ect modifiers may cause treatment effect estimates in any set
f comparisons to be heterogeneous and to deviate from the
rue treatment effect in the target population. This can be an
ssue in any synthesis of evidence for decision making, includ-
ng pairwise meta-analysis. It may lead to inconsistencies
ithin a network of evidence if the distribution of effect modi-
ers across that network is unbalanced.
In this article, we present a case study in which the direct evidence
ppeared, initially to cast doubt on the indirect evidence. Additional
ead-to-head data subsequently became available that were, how-
ever, consistent with the original indirect evidence. The case study
is based on a synthesis of evidence of three granulocyte colony–
stimulating factors (G-CSFs) for the reduction of incidence of fe-
brile neutropenia (FN) during chemotherapy carried out in the
context of a cost-effectiveness analysis. Both indirect and direct
comparisons showed primary pegfilgrastim to be significantly su-
perior to no primary G-CSFs: the single head-to-head trial in the
original data set, however, showed a markedly greater effect size
than that estimated from the indirect evidence.
Our approach is as follows: we begin with the original data set
and show how the consistency of the direct and indirect evidence
can be assessed using a “node-splitting” approach [13]. We con-
sider whether strength of evidence should lead us to prefer direct,
indirect, or pooled evidence for decision making. We then repeat
our analyses for the updated data set. We also use predictive
cross-validation [14,15] to consider whether the original single pri-
ary pegfilgrastim versus no primary G-CSF trial could be consid-
red a statistical outlier with respect to the time 1 and time 2 data
ets.
The case study highlights the issues that need to be considered
hen deciding whether to combine direct and indirect evidence
nd also raises the question of detecting inconsistency in standard
airwise meta-analysis. We can also contrast Bayesian model
hecking techniques facilitated by flexible packages such as the
reely available WinBUGS software [16], with commonly used fre-
uentist methods. The case study raises questions about how to
nterpret NICE Methods Guidance and advice given in the Co-
hrane Handbook in cases in which a decision must be made be-
ween more than two treatments.
Methods
Clinical context and sources of evidence for synthesis
G-CSFs may be administered to patients receiving chemotherapy
as primary prophylaxis (in every chemotherapy cycle from cycle 1)
or as secondary prophylaxis (in all remaining cycles after a neu-
tropenic event such as FN and prolonged severe neutropenia). The
motivation for this evidence synthesis exercise was to inform an
analysis of the cost-effectiveness of primary prophylaxis with G-
CSFs in adults with solid tumors or lymphoma. The decision prob-
lem guided the search strategy used to identify relevant evidence.
Studies were excluded if they involved children or patients with
conditions outside the decision population (i.e., those with leuke-
mia, myeloid malignancies, or myelodysplastic syndromes). In
line with previous systematic reviews [17,18], we included trialscomparing either a) two different G-CSFs, both given as primary
prophylaxis, or b) a G-CSF given as primary prophylaxis versus no
primary prophylaxis. No primary prophylaxis could include no
G-CSF provision, placebo, or secondary G-CSF prophylaxis.
Two systematic reviews and meta-analyses of G-CSFs in rela-
tion to reducing FN events were identified: Kuderer et al. [17] and
into et al. [18]. These meta-analyses included 20 trials, with head-
o-head comparisons of each G-CSF (given as primary prophylaxis)
ersus no primary G-CSF, as well as trials of primary pegfilgrastim
ersus primary filgrastim. The direct evidence comparing primary
egfilgrastim with no primary G-CSF consisted of a single head-
o-head trial [19]. We refer to these 20 trials as the time 1 evidence
ase throughout our analysis.
Subsequently, an updated systematic review of G-CSF trials
as performed [20] that identified five additional relevant ran-
omized, controlled trials (RCTs). The additional studies included
our further RCTs of primary pegfilgrastim compared to no pri-
ary G-CSF (reported in three references [21–23]), and one further
CT of primary filgrastim compared to no primary G-CSF [24].
hese additional studies would not have been available to support
decision made at the time that the previous systematic reviews
ere performed. We refer to the updated evidence base of 25 trials
s the time 2 evidence base throughout our analysis. Figure 1
hows the evidence network at time 1 and time 2, and the full set
f trial data is shown in Table 1. A table giving further clinical
ackground on these studies is included in the Appendix. Al-
hough all met the inclusion criteria, there are differences be-
ween the trials in terms of the cancer type and stage, patient age,
nd chemotherapy regimen. There was no reason, however, to
ssume a priori that these differences would be significant effect
odifiers, and both previous systematic reviews had pooled stud-
es despite these differences. There was no indication that any of
he four sets of trials was different in terms of clinical heteroge-
eity from the others.
Statistical methods
Odds ratios (ORs) for each study were calculated and conventional
pairwise meta-analyses were performed on the time 1 and time 2
data using the STATA command metan, which implements the
DerSimonian and Laird method for random-effects meta-analysis
[25]. Statistical analyses of the evidence network were carried out
in a Bayesian Markov chain Monte Carlo (MCMC) framework using
the WinBUGS software [16]. We applied Bayesian random-effects
MTC synthesis to both the time 1 and time 2 data sets [4]. Under
random effects, it is assumed that the true treatment effects in
trial j comparing treatments A and B are sampled from a random-
effects distribution jABN(dAB, )
2. We began our analysis of each
data set by fitting the standard MTC synthesis, which assumes
consistency between direct and indirect evidence (so that dBC 
AC  dAB) and a single between-trials variance for each compari-
son. We used the posterior mean deviance corrected for the satu-
rated model (mean residual deviance) as a measure of goodness of
fit; a model that fits the data well should have a residual deviance
close to the number of data points (26), which is this case is the
number of study arms.
To assess whether direct evidence was consistent with indi-
rect, we then fitted a model relaxing the consistency assumption.
In this model, the treatment effects of primary pegfilgrastim ver-
sus no primary G-CSF (dPeg,Null), primary pegfilgrastim versus pri-
ary filgrastim (dPeg,Fil) and primary filgrastim versus no primary
-CSF (dFil,Null) are assumed to be completely unrelated (compared
to the standard MTC in which dPegNull  dPeg,Fil  dFil,Null). This
model is therefore equivalent to separate meta-analyses for each
relative treatment effect where head-to-head trials exist, except
that a common between-trials variance term is assumed. The
treatment effects given by this model are based solely on direct
evidence. However, we can use these results to calculate estimates
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955V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 5 3 – 9 6 0of treatment effect based solely on indirect evidence (e.g., the es-
timate for the treatment effect of primary pegfilgrastim vs. no
primary G-CSF based on indirect evidence alone is given in the
inconsistency model by dPeg,Fil  dFil,Null) The model can therefore
e used to compare the direct and indirect estimates. A Bayes-
an two-sided P value can be readily constructed in Bayesian
CMC by determining the proportion of iterations in which the
irect estimate exceeds the indirect. This procedure is equiva-
ent to node-splitting methods for checking the consistency of
TC [13].
The time 1 analyses suggested that one particular trial by Vogel
t al. [19], which was the only trial comparing primary pegfilgras-
im with no primary G-CSF in the time 1 data set was giving results
nconsistent with the rest of the evidence. To explore the influence
f this specific study, we carried out Bayesian predictive cross-
alidation analyses [14,15]. Here the data were reanalyzed under a
andom-effects model excluding the Vogel et al. trial. We then gen-
rated a prediction for the relative treatment effect that would be
bserved in a “new trial” of primary pegfilgrastim versus no pri-
ary G-CSF of exactly the same size as the Vogel et al. trial. In the
Fig. 1 – Network of trials forime 1 analysis, this prediction is based solely on the indirect evi- fence. At time 2, we could generate a prediction for the Vogel et al.
rial based on the consistency model (using the totality of the re-
aining evidence, both direct and indirect). Alternatively, we can
ssess whether the Vogel et al. trial is consistent with the other
rimary pegfilgrastim versus no primary G-CSF trials by forming
he prediction only from the remaining direct evidence in the in-
onsistency model. Predictive cross-validation estimates the pre-
icted treatment effect based on the remaining data, the between-
rials variation, the uncertainty in both these quantities, and the
ize of the Vogel trial. It incorporates the additional uncertainty in
rawing a new sample from the random effects distribution and is
hus a more conservative procedure than node splitting, which is
oncerned with the equivalence of mean treatment effects. Bayes-
an two-sided cross-validation P values were compared to their
xpected order statistics, 1/(n 1) (n being the number of trials) as
hey reflect the extreme of n P values that could be calculated.
WinBUGS code and data sets are given in Appendix A1, which
an be found at doi:10.1016/j.val.2011.05.008. For all analyses, con-
ergence was checked using the Gelman Rubin statistics available
n WinBUGS. Posterior summaries are based on 50,000 samples,
ed treatment comparison.mixollowing an initial 50,000 burn-in.
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The study-specific odds ratios (ORs) and results from conventional
random-effects pairwise meta-analyses and I2 values are shown in
Table 1. The degree of heterogeneity in all pairwise syntheses is
moderate to large, except that in the comparison of primary peg-
filgrastrim with primary filgrastrim, the I2 value was zero. Inspec-
ion of the study ORs suggests, however, that this reflects the small
ample size of most of these studies because the crude ORs are in
act highly heterogeneous.
Table 2 presents the estimates generated for the relative effi-
acy of G-CSFs at both time 1 and time 2. Median ORs, with 95%
redible intervals, are presented for the four contrasts for which
ead-to-head trials are present. At each time point, three sets of
esults are set out: the direct and indirect estimates based on the
nconsistency model and the combined MTC estimates assuming
onsistency. At time 1, direct estimates of each contrast differ
uite markedly from indirect estimates with Bayesian predictive P
alues all at 0.027, although there is a slight overlap in confidence
ntervals. The same P value is obtained with every contrast be-
ause there can only be a single “inconsistency” in a triangular
etwork, no matter which edge is compared to the other two. As
Table 1 – Incidence of febrile neutropenia (FN) in all studie
Study Total no.
(arm 1)
FN rate
Primary pegfilgrastim
*Hecht et al., 2009 [23] 123 3/123
Vogel et al., 2005 [19] 463 6/463
*Balducci et al., 2007 [21]: solid
tumor
343 14/343
*Balducci et al., 2007: NHL [21] 73 11/73
*Romieu et al., 2007 [22]: cycle 1
only
30 4/30
Pooled result: mean (95% CI) OR Time 1: 0.07 (0.
Primary filgrastim
*del Giglio et al., 2008 [24] 276 34/276
Doorduijn et al., 2003 [36] 197 72/197
Osby et al., 2003 [37]: CHOP 101 34/101
Osby et al., 2003 [37]: CNOP 125 40/125
Zinzani et al., 1997 [38] 77 4/77
Pettengell et al., 1992 [39] 41 9/41
Timmer-Bonte et al., 2005 [40] 90 16/90
Trillet-Lenoir et al., 1993 [41] 65 17/65
Crawford et al., 1991 [42] 95 38/95
Fossa et al., 1998 [43] 129 25/129
Pooled result: mean (95% CI) OR Time 1: 0.43
Primary lenograstim
Chevallier et al., 1995 [44] 61 36/61
Gisselbrecht et al., 1997 [45] 82 52/82
Bui et al., 1995 [46]: cycle 1 22 5/22
Gebbia et al., 1994 [47] 23 5/23
Gebbia et al., 1993 [48] 43 5/43
Pooled result: mean (95% CI) OR
Primary pegfilgrastim
Green et al., 2003 [49] 77 10/77
Holmes et al., 2002 [50]: phase III 149 14/149
Holmes et al., 2002 [51]: phase II 46 5/46
Grigg et al., 2003 [53] 14 0/14
Vose et al., 2003 [52]: cycles 1
and 2
29 6/29
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone;
trone, prednisone; G-CSF, granulocyte colony–stimulating factor; NH
* Studies added at time 2 as a result of updated search.xpected, the MTC results from the consistency model, which cools direct and indirect evidence, lie between the direct and in-
irect estimates.
At time 2, considerably more data are available on the primary
egfilgrastim versus no primary G-CSF contrast. Here there is no
vidence to suggest overall inconsistency: direct and indirect es-
imates are very close and the P value is now 0.87. Indeed the
stimates for the primary pegfilgrastim versus no primary G-CSF
ffect at time 2 are very similar to the indirect evidence at time 1.
his suggests that the inconsistency is between the Vogel et al.
rial, in which risk reduction was particularly strong (from 17% to
%), and the rest of the evidence. For completeness, Table 2 in-
ludes further statistics. The between-trial SD suggests distinct
eterogeneity in the data, particularly at time 2, where the lower
imit is far from zero. Where there is inconsistency in the data, a
odel that imposes a consistency assumption will report more
eterogeneity than one that relaxes this assumption because dis-
greement between direct and indirect does not need to be “ex-
lained” by heterogeneity in the latter case. This can be seen in the
eterogeneity estimated by each model at time 1. At time 2, how-
ver, there is no difference in heterogeneity between consistency
nd inconsistency models, further indicating the agreement be-
ween all evidence sources. The residual deviance statistics are
rophylactic G-CSFs.
Total no.
(arm 2)
FN rate % Odds ratio, mean
(95% CI)
No primary G-CSF
118 10/118 8 0.27 (0.07–1.01)
3 465 78/465 17 0.07 (0.03–0.15)
343 34/343 10 0.39 (0.20–0.74)
73 27/73 37 0.30 (0.14–0.67)
29 5/29 17 0.74 (0.18–3.08)
15) I2 not calculated; Time 2: 0.26 (0.12–0.58), I2  73%
No primary G-CSF
72 26/72 36 0.25 (0.14–0.45)
192 86/192 45 0.71 (0.48–1.07)
104 52/104 50 0.51 (0.29–0.89)
125 62/125 50 0.48 (0.19–0.80)
72 15/72 21 0.21 (0.07–0.66)
39 17/39 44 0.36 (0.14–0.96)
85 27/85 32 0.46 (0.23–0.94)
64 34/64 53 0.31 (0.15–0.66)
104 80/104 77 0.20 (0.11–0.37)
130 38/130 29 0.58 (0.33–1.04)
–0.58), I2  47.8%; Time 2: 0.40 (0.30–0.54), I2  51%
No primary G-CSF
59 42/59 71 0.58 (0.27–1.25)
80 62/80 78 0.50 (0.25–1.00)
26 15/26 58 0.22 (0.06–0.76)
28 18/28 64 0.15 (0.04–0.54)
43 14/43 33 0.27 (0.09–0.84)
0.37 (0.23–0.60), I2  19%
Primary filgrastim
75 15/75 20 0.60 (0.25–1.43)
147 27/147 18 0.46 (0.23–0.92)
25 2/25 8 1.40 (0.25–7.81)
13 1/13 8 0.29 (0.01–7.70)
31 6/31 19 1.09 (0.31–3.85)
onfidence interval; CNOP, cyclophosphamide, vincristine, mitoxan-
-Hodgkin’s lymphoma; OR, odds ratio.s of p
%
2
1.
4
15
13
03–0.
12
37
34
32
5
22
18
26
40
19
(0.32
59
63
23
22
12
13
9
11
0
21
CI, c
L, nonlose to the number of data points (study arms) in all analyses and
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957V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 5 3 – 9 6 0do not distinguish the models. This is because random-effects
models tend to fit the data quite well, regardless of the degree of
heterogeneity.
The cross-validation analyses (Table 3) focus on whether the
results as extreme as those reported in the Vogel et al. study of
primary pegfilgrastim versus no primary G-CSF would be ex-
pected, based on a) the time 1 indirect evidence on this contrast, b)
the totality of the remaining evidence (direct and indirect) at time
2, and c) the additional primary pegfilgrastim versus no primary
G-CSF information available at time 2. At time 1, the P value is
0.047, on the margin of conventional significance testing. By time
2, the P value is 0.013, providing strong evidence that the true
treatment effect in the trial is not consistent with expectations
based on the other trials. This is true even if the only trials in-
Table 2 – Posterior odds ratios for febrile neutropenia (med
models with and without the assumption of consistency.
Treatment
contrast
Time 1 (20 trials, 40 arms)
Consistency not assumed
Con
as
Direct OR
(95% CrI)
Indirect OR
(95% CrI)
P
value
Comb
OR
Primary filgrastim
vs.no primary G-
CSF
0.43 (0.30–0.58) 0.10 (0.02–0.33) 0.027 0.38
Primary
pegfilgrastim vs.
no primary G-CSF
0.06 (0.02–0.19) 0.27 (0.13–0.53) 0.17
Primary
pegfilgrastim vs.
primary filgrastim
0.62 (0.35–1.17) 0.15 (0.04–0.46) 0.45
Primary
lenograstim vs.
no primary G-CSF
0.35 (0.20–0.59) NA NA 0.34
Heterogeneity
(between-trial SD
log OR, mean
(95% CI)
0.32 (0.04–0.66) 0.42
Mean residual
difference
39.7
For each comparison of treatments A and B, the odds ratios reported
odds ratio from a random-effects distribution.
CI, confidence interval; CrI, credible interval; G-CSF, granulocyte c
available; OR, odds ratio.
Table 3 – Cross-validation of the Vogel et al. [19] trial.
Source of estimate Febrile
neutropenia,
% (95% CI)
P
value
Expected
P value
Observed, Vogel et al. [19] 1.3 (0.6–2.8)
Predicted, indirect evidence,
time 1
5.7 (1.9–13.1) 0.047 0.048
Predicted, totality of remaining
evidence, time 2
6.1 (3.0–10.8) 0.013 0.038
Predicted, remaining direct
evidence, time 2
7.3 (2.8–15.4) 0.01 0.17
Observed and predicted percentage of febrile neutropenia in the
Vogel et al. [19] trial, with two-sided Bayesian P values and expected
P value. Based on most extreme order statistic for N  1 samples
from a uniform distribution, where N is the number of trials gener-m
ating the prediction.cluded in the comparison are the other trials of primary pegfilgras-
tim versus no primary G-CSF available at time 2 (P  0.010).
These P values do, however, need to be considered in the light
of the implied number of P values that could be generated. The
Vogel et al. trial can be seen as the most extreme of all the trials in
the synthesis. At time 1, given that there are 20 trials, the P value of
.047 should be compared to the most extreme expected order
tatistic for 20 samples from a uniform distribution, P  0.048 (1/
1). This suggests that it is not unlikely to find one trial as extreme
s the Vogel et al. trial given the heterogeneity in the other time 1
rials. However, at time 2, the Bayesian P values, when compared
o their expected order statistics, confirm that the Vogel et al. trial
s not compatible with the totality of the other time 2 evidence, nor
ven with the four other trials of primary pegfilgrastim versus no
rimary G-CSF.
Discussion
Where the available evidence forms a connected network, as for
example in Figure 1, it is possible to estimate the relative efficacy
of any two treatments either directly from the head-to-head trials
or indirectly from their performance against one or more common
comparators. This gives us three possible estimates for each treat-
ment effect: direct, indirect, and pooled (MTC). We used this case
study to illustrate a range of methods for checking the consistency
of direct and indirect estimates. Consider the situation at time 1.
The Bayesian P value comparing the direct and indirect evidence
would strongly suggest that the two sources are inconsistent. The
cross-validation procedure is considerably more conservative and
does not reject the possibility of consistency so emphatically. This
is because it is based on the predictive distribution of “new” trials,
whereas the node-splitting comparison of direct and indirect evi-
dence is based on the posterior mean effects. Nevertheless, esti-
and 95% credible interval) at time 1 and time 2 under
Time 2 (25 trials, 50 arms)
ncy
ed Consistency not assumed
Consistency
assumed
(MTC)
CrI)
Direct OR
(95% CrI)
Indirect OR
(95% CrI)
P
value
Combined (MTC)
OR (95% CrI)
0.53) 0.40 (0.27–0.56) 0.36 (0.14–0.89) 0.87 0.39 (0.28–0.54)
0.33) 0.23 (0.12–0.43) 0.25 (0.12–0.55) 0.24 (0.15–0.39)
0.85) 0.64 (0.33–1.30) 0.59 (0.30–1.22) 0.62 (0.38–1.04)
0.61) 0.34 (0.18–0.61) NA NA 0.34 (0.19–0.60)
0.78) 0.44 (0.21–0.76) 0.42 (0.20–0.73)
49.8 49.5
osterior medians of the quantity exp(dAB), where dAB is the mean log
–stimulating factor; MTC, mixed treatment comparison; N/A, notian
siste
sum
ined
(95%
(0.26–
(0.09–
(0.25–
(0.19–
(0.16–
40.1
are p
olonyates of treatment effect at time 1 vary substantially depending
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958 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 5 3 – 9 6 0on whether they draw on direct, indirect, or pooled evidence. This
raises the question: which estimate should be used to represent
treatment efficacy in economic models?
The Cochrane collaboration states that direct evidence should
be accorded a higher rating in the evidence hierarchy than, and
preferred to, indirect [7]. The NICE Guide to the Methods of Tech-
nology Appraisal [27] allows for an MTC combining direct and in-
direct evidence to be presented as a subsidiary analysis. It re-
quires, however, the reference case analysis to be based on direct
evidence. Consider the situation in which the decision problem is
that of whether to adopt primary prophylaxis with pegfilgrastim
or use no primary G-CSF prophylaxis. At time 1, an investigator
charged with this decision problem and following the guidance
given by Cochrane and NICE would have based their analysis ex-
clusively on the Vogel et al. trial, this being the only direct evi-
dence. Possibly they would have felt quietly confident in excluding
the indirect evidence, in view of the apparent discordance be-
tween the mean treatment effects obtained from direct and indi-
rect sources. A key point of interest in this illustration, however, is
that it offers us the benefit of hindsight. At time 2, we have addi-
tional evidence available that provides an independent (direct)
estimate of the “difficult” primary pegfilgrastim and no primary
G-CSF comparison. With the additional evidence, the direct and
indirect evidence appears consistent; moreover, the direct esti-
mate at time 2 is in line with the indirect estimate at time 1 rather
than the direct estimate at that time.
Following accepted wisdom would have produced what seems
to be, in the light of later evidence, the “wrong” answer in a time 1
analysis of the efficacy of primary pegfilgrastim versus no primary
G-CSF. The actual decision problem in this example, however, in-
volved a simultaneous comparison of all G-CSFs. In this situation,
the problem with guidance favoring direct evidence is more fun-
damental—it is impossible to follow. This is because it is not pos-
sible to construct a coherent cost-effectiveness analysis (CEA) for
multiple treatments based on incremental net benefit unless the
statistical model for the treatment effects guarantees consistency
(as the MTC does). It follows that a trial that is “direct” evidence for
one comparison is “indirect” evidence for another. This is why
indirect comparisons and MTC analyses have become, in practice,
routine whenever three or more treatments must be compared in
the same CEA.
Once it is accepted that the estimates used in the analysis must
be internally consistent, it is more meaningful to consider which
trials to include in the analysis rather than whether to pool direct
and indirect evidence. In our illustrative example, the inconsis-
tency is between one trial (Vogel et al.) and the others. At time 1,
the statistical evidence for the presence of inconsistency is at best
marginal. At time 2, the issue is clearer. Direct and indirect evi-
dence are broadly consistent; one could again “prefer” direct evi-
dence if the CEA concerned only primary pegfilgrastim versus no
primary G-CSF, although we would argue there are good reasons
for preferring a more robust estimate from the broader evidence
base. However, this does not solve the problem of inconsistency,
which exists between the Vogel et al. trial and other trials making
the same comparison rather than between direct and indirect ev-
idence. This shows that inconsistency, given by some as a reason
for avoiding the synthesis of direct and indirect evidence in an
MTC, can also be a problem for pairwise meta-analyses.
The decision as to which trials to include in the analysis should
be guided by their relevance to the target population of the deci-
sion being informed. If the patient population in the Vogel et al.
trial matches the decision population more closely than other
studies, and it is reasonable to suppose that these differences
might modify relative treatment effects, then it may be appropri-
ate to base the decision on its results. From a description of the
clinical characteristics of the trials (see Appendix, which can be
found at doi:10.1016/j.val.2011.05.008) differences can be identi- tfied between the Vogel et al. trial and other trials of primary peg-
filgrastim versus no primary G-CSF, such as the use of docetaxel
chemotherapy and a lower mean age of participants. One might
point to such differences to explain the strong risk reduction effect
observed in the Vogel et al. trial. However, these are post hoc at-
tempts to justify the observed difference between the Vogel et al.
trial and other head-to-head trials making the same comparison.
There are also similarities between the Vogel et al. trial and the
other trials making the same comparison—the Romieu et al. [27]
trial in particular (the results of which disagree most strongly with
Vogel et al.). Furthermore, these explanations do not identify the
Vogel et al. trial as distinct from all the other trials across the
network. Both the del Giglio et al. [24] and Holmes et al. phase III
[51] trials appear to have study characteristics very similar to
those of the Vogel et al. trial (see Appendix A3 found at doi:10.1016/
j.jval.
2011.05.008).
Guidance is required from decision makers as to whether such
criteria can be used to identify trials that can be excluded from the
analysis as they are too dissimilar from the decision population to
be relevant. One concern is that this can lead to accusations of
“cherry-picking” studies that favor a particular treatment. To
avoid this accusation, exclusion criteria should be clearly defined
before identifying the evidence, and it may be advisable to include
all available studies unless they are clearly not relevant. In our
example, it might seem that this is not a major concern because
both direct and indirect estimates suggest that pegfilgrastim is
more efficacious than no primary G-CSF. However, differences in
estimates of treatment effect can have a marked impact on cost-
effectiveness, even when they agree over the statistically superi-
ority of one treatment over another. None of this changes the basic
requirement that when a choice is being made among three or
more treatments, estimates of relative treatment effect must form
a consistent set.
The Bayesian synthesis, node-splitting, and cross-validation
approaches are not the only methods that could have been used. A
simple frequentist approach such as that presented by Bucher et
al. [28], could also have been used. This would be implemented by
carrying out a standard meta-analysis of the trials on each “edge”
of the triangle in the Figure 1 network, forming an indirect esti-
ate of the primary pegfilgrastim versus no primary G-CSF effect
nd finally comparing this to the direct evidence. In this particular
ase study, the Bucher et al. method has a potential drawback.
andom-effects estimates can be obtained for two of the con-
rasts, but because there is only one pegfilgrastim versus no pri-
ary G-CSF trial at time 1, one must use a fixed-effects estimate
or this contrast.
The Bayesian MCMC method in the WinBUGS package has al-
owed us to fit a random-effects model with a shared variance to
ll four contrasts at the same time. This is a more reasonable
odel and is considerably more conservative. After all, if the evi-
ence on the other contrasts is heterogeneous, we would expect
vidence on primary pegfilgrastim versus no primary G-CSF to also
e heterogeneous. In the Bucher et al., approach, a statistical test
or consistency of indirect and direct evidence (at time 1) would
ive a P value of 0.01 (see Appendix A2 found at doi:10.1016/
.val.2011.05.008). In our view, this exaggerates the inconsistency
n the evidence because it fails even to recognize that the primary
egfilgrastim versus no primary G-CSF efficacy estimate should be
een as the mean of a random-effects distribution, let alone the
eed to compare the specific trial result to a suitable predictive
istribution. The Bucher et al. approach would, if used to inform
n economic model, considerably understate uncertainty in the
fficacy of pegfilgrastim versus placebo compared to the more
onservative shared-variance assumption (this can be seen by
omparing the 95% credible interval of 0.02–0.19 for this parame-
er given in Table 1 with the 95% confidence interval of 0.03–0.15
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j.val.2011.05.008).
Another class of models that could be applied are those that
allow for different levels of between-trial variation in each of the
four contrasts [12]. Table 1 presents no strong evidence against the
omogeneous variance model that we have assumed, although a
odel with lower heterogeneity in the head-to-head trials could
lso be considered. It is unclear, however, whether this would
hange conclusions in this case. A persistent difficulty in all meta-
nalyses is the paucity of information on between-trials variation.
eterogeneous variance methods would require informative pri-
rs on aspects of variation and covariation, and this is currently an
ctive area of research.
What lessons can be learned from this example? Clearly, there
s a debate to be had about the interpretation of random-effects
odels in health technology assessment [29,30]. But, setting that
side, it suggests that, rather than prefer direct evidence, a better
trategy may be to use all available evidence, both direct and in-
irect, subject to a rigorous, prespecified set of trial inclusion cri-
eria, and to careful post hoc checks for consistency, although
hese will seldom have enough power to detect potential prob-
ems. Empirical studies conducted to date in which direct and in-
irect estimates have been compared would support this view [8].
n cases in which the two have been discordant, there are clear
ndications that direct and indirect estimates were based on dif-
erent protocols or doses [8,11,31]. Song et al. [32] have even sug-
ested that indirect evidence may be less biased in some circum-
tances. Another approach is the use of MTC methods to both
stimate “novelty” bias [33] or bias associated with markers of
ower trial quality [34] and simultaneously adjust for these biases.
hese approaches probably require further evaluation before they
ould be adopted for routine use, but they are among a growing set
f techniques designed to adjust for potential bias, without requir-
ng a demonstration of a significant bias [35].
Conclusions
We present an example in which the indirect evidence gave mark-
edly better predictions of future trial results than the direct evi-
dence. Doubtless, other examples could be found in which the
opposite is true. However, if the AB, AC, and BC evidence is con-
sidered equally representative of the target population and
equally vulnerable to effect modification, then the general rule, in
line with the overall aim of meta-analysis, should be to combine
all sources of relevant information to obtain the most robust co-
herent estimates. Bayesian methods offer a flexible approach for
the synthesis of a network of evidence and the identification of
subsets of the evidence that are mutually inconsistent.
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